CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 140 enrolled
Drug / intervention
Restylane Defynedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03624816
NCT03624816N/ACompleted

A Randomized, No-treatment Controlled, Evaluator-blinded, Multi-center Study to Evaluate the Effectiveness and Safety of Restylane Defyne in the Chin for Augmentation and Correction of Chin Retrusion

Galderma R&D·interventional·Posted Aug 10, 2018·Updated Oct 6, 2022

In Brief

A clinical study evaluating Restylane Defyne for Chin Retrusion and Chin Augmentation. Completed, enrolled 140 participants across 11 sites.

Detailed Summary

To demonstrate the effectiveness of Restylane Defyne for chin augmentation and correction of chin retrusion by demonstrating the superiority in responder rates relative to no treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 10, 2018
Enrollment StartAug 21, 2018
Primary CompletionMar 7, 2019
Study CompletionFeb 20, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.9 years ago

Interventions

Restylane Defynedevice

hyaluronic acid dermal filler gel